Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

被引:22
|
作者
Bastidas-Mora, Gabriela [1 ,2 ]
Bea, Silvia [1 ,2 ,3 ,4 ,5 ]
Navarro, Alba [3 ,5 ]
Gine, Eva [1 ,2 ,3 ,5 ]
Costa, Dolors [1 ,2 ,3 ,5 ]
Delgado, Julio [1 ,2 ,3 ,5 ]
Baumann, Tycho [1 ,2 ,5 ,6 ]
Magnano, Laura [1 ,2 ,3 ]
Rivas-Delgado, Alfredo [1 ,2 ,3 ]
Villamor, Neus [1 ,2 ,3 ,5 ]
Colomer, Dolors [1 ,2 ,3 ,4 ,5 ]
Lopez-Guerra, Monica [1 ,2 ,3 ,5 ]
Rozman, Maria [1 ,2 ,3 ]
Balague, Olga [1 ,2 ,3 ,5 ]
Martinez, Daniel [1 ,2 ,5 ]
Baptista, Maria Joao [7 ]
Escoda, Lourdes [8 ]
Alcoceba, Miguel [5 ,9 ]
Blanes, Margarita [10 ]
Climent, Fina [11 ]
Campo, Elias [1 ,2 ,3 ,4 ,5 ]
Wotherspoon, Andrew [12 ]
Lopez-Guillermo, Armando [1 ,2 ,3 ,4 ,5 ]
Matutes, Estella [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[2] Hosp Clin Barcelona, Hematopathol Sect, Pathol Dept, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer IDIBAP, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[6] Hosp 12 Octubre, Serv Hematol, Madrid, Spain
[7] Josep Carreras Leukaemia Res Inst IJC, ICO Hosp Germans Trias & Pujol, Barcelona, Spain
[8] ICO Hosp Joan XXIII, Tarragona, Spain
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, Canc Res Inst Salamanca IBMCC USAL CSIC, Salamanca, Spain
[10] Hosp Gen Univ Elda, Alicante, Spain
[11] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona, Barcelona, Spain
[12] Royal Marsden NHS Fdn Trust, London, England
关键词
splenic marginal zone lymphoma; histological transformation; complex karyotype; prognostic factors; survival; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; VILLOUS LYMPHOCYTES; RESPONSE CRITERIA; RISK; RITUXIMAB; SURVIVAL; SPLENECTOMY; MULTICENTER; SERIES;
D O I
10.1111/bjh.17815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0 center dot 05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4 center dot 025, P = 0 center dot 05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3 center dot 89, P < 0 center dot 001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4 center dot 92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5 center dot 294, P = 0 center dot 016) and lack of CR (HR 2 center dot 67, P < 0 center dot 001).
引用
收藏
页码:146 / 155
页数:10
相关论文
共 50 条
  • [21] Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
    Thieblemont, Catherine
    Davi, Frederic
    Noguera, Maria-Elena
    Briere, Josette
    Bertoni, Francesco
    Zucca, Emanuele
    Traverse-Glehen, Alexandra
    Felman, Pascale
    Berger, Francoise
    Salles, Gilles
    Coiffier, Bertrand
    ONCOLOGY-NEW YORK, 2012, 26 (02): : 194 - 202
  • [22] Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era
    Starr, Adam G.
    Caimi, Paolo F.
    Fu, PingFu
    Massoud, Mira R.
    Meyerson, Howard
    Hsi, Eric D.
    Mansur, David B.
    Cherian, Sheen
    Cooper, Brenda W.
    De Lima, Marcos J. G.
    Lazarus, Hillard M.
    Gerson, Stanton L.
    Jagadeesh, Deepa
    Smith, Mitchell R.
    Dean, Robert M.
    Pohlman, Brad L.
    Hill, Brian T.
    William, Basem M.
    HEMATOLOGY, 2017, 22 (07) : 405 - 411
  • [23] The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma
    Hockley, Sarah L.
    Else, Monica
    Morilla, Alison
    Wotherspoon, Andrew
    Dearden, Claire
    Catovsky, Daniel
    Gonzalez, David
    Matutes, Estella
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (03) : 347 - 354
  • [24] Hereditary ovarian carcinomas: clinico-biological features and treatment
    Floquet, Anne
    Stoeckle, Eberhard
    Croce, Sabrina
    Longy, Michel
    Mc Grogan, Gaetan
    Barouk, Emmanuelle
    Bubien, Virginie
    Garbay, Delphine
    Joly, Eglantine
    Guyon, Frederic
    BULLETIN DU CANCER, 2014, 101 (02) : 167 - 174
  • [25] Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
    Kalpadakis, Christina
    Pangalis, Gerassimos A.
    Angelopoulou, Maria K.
    Sachanas, Sotirios
    Vassilakopoulos, Theodoros P.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (01) : 65 - 72
  • [26] Splenic marginal zone lymphoma: from genetics to management
    Arcaini, Luca
    Rossi, Davide
    Paulli, Marco
    BLOOD, 2016, 127 (17) : 2072 - 2081
  • [27] Splenic marginal zone lymphoma
    Oscier, D
    Owen, R
    Johnson, S
    BLOOD REVIEWS, 2005, 19 (01) : 39 - 51
  • [28] Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma
    Else, Monica
    Marin-Niebla, Ana
    de la Cruz, Fatima
    Batty, Paul
    Rios, Eduardo
    Dearden, Claire E.
    Catovsky, Daniel
    Matutes, Estella
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (03) : 322 - 328
  • [29] Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era
    Perrone, Salvatore
    D'Elia, Gianna Maria
    Annechini, Giorgia
    Ferretti, Antonietta
    Tosti, Maria Elena
    Foa, Robin
    Pulsoni, Alessandro
    LEUKEMIA RESEARCH, 2016, 44 : 53 - 60
  • [30] Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival
    Yang, Zhen
    Liu, Lianshuang
    Leng, Kaiming
    Shi, Guangjun
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (12) : 7206 - 7216